What are the indications, dosing, contraindications, and alternative treatments for Xofluza (baloxavir marboxil)?

Xofluza (Baloxavir Marboxil) for Influenza

Indications

Xofluza is FDA-approved for treatment of acute uncomplicated influenza in patients ≥5 years of age who have been symptomatic for no more than 48 hours, and for post-exposure prophylaxis following contact with an influenza-infected individual. 1

• Treatment indication: Approved for otherwise healthy patients or those at high risk of developing influenza-related complications 1
• Prophylaxis indication: Approved for post-exposure prevention in patients ≥5 years following contact with an influenza case 1
• Critical timing: Must be administered within 48 hours of symptom onset for treatment or following exposure for prophylaxis 2, 1

Important Age Restriction

• NOT indicated for children <5 years of age due to significantly higher incidence of treatment-emergent resistance in this population 1
• Recent data in infants <1 year showed safety but resistance concerns remain 3

Dosing

Xofluza is administered as a single oral dose based on body weight, which can be a major adherence advantage over 5-day oseltamivir regimens. 2, 1

Weight-Based Dosing (Same for Treatment and Prophylaxis)

For patients ≥5 years: 2, 1

• <20 kg: 2 mg/kg as single dose
• 20 kg to <80 kg: 40 mg as single dose
• ≥80 kg: 80 mg as single dose

Administration Considerations

Critical drug-food interactions exist that significantly reduce efficacy: 2, 1

• Avoid coadministration with: dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (calcium, iron, magnesium, selenium, zinc) 2, 1
• These polyvalent cations chelate baloxavir and reduce absorption, leading to loss of antiviral efficacy 4
• May be taken with or without food (non-dairy) 1
• Can be administered via feeding tube 2

Renal/Hepatic Dosing

• No dose adjustment needed for mild-to-moderate hepatic or renal impairment 5

Contraindications

Xofluza is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. 1

• Hypersensitivity reactions including anaphylaxis, angioedema, urticaria, and erythema multiforme have been reported 1
• Initiate appropriate treatment immediately if allergic-like reaction occurs 1

Special Populations Where NOT Recommended

Several high-risk populations should avoid baloxavir: 2

• Severely immunocompromised patients: Not recommended as monotherapy due to resistance concerns 2
• Pregnant patients: Not recommended 2
• Breastfeeding patients: Not recommended 2
• Children <5 years: Not indicated due to high resistance rates 1

Adverse Events

Baloxavir has a favorable safety profile comparable to or better than oseltamivir. 6, 7

Common Adverse Events in Adults/Adolescents (≥1%): 1

• Diarrhea (3%)
• Bronchitis (3%)
• Nausea (2%)
• Sinusitis (2%)
• Headache (1%)

Common Adverse Events in Pediatric Patients 5-<12 years (≥5%): 1

• Vomiting (5%)
• Diarrhea (5%)

Meta-analysis data shows baloxavir had significantly lower incidence of adverse events compared to oseltamivir in outpatients (p=0.03). 7

Efficacy

Baloxavir demonstrates superior viral load reduction compared to oseltamivir and similar symptom alleviation times. 6, 8

Clinical Outcomes

• Time to symptom alleviation: Median 53.7 hours with baloxavir vs 80.2 hours with placebo (p<0.001), similar to oseltamivir 6
• Viral load reduction: Significantly greater reductions at 24 hours post-dose compared to both placebo and oseltamivir 6
• Transmission prevention: 29% relative risk reduction in transmission to household contacts by day 5 (adjusted incidence 9.5% vs 13.4% placebo, p=0.01) 8

Inpatient Data

• Mortality reduction trend in hospitalized patients (p=0.06) 7
• Significantly shorter hospitalization compared to oseltamivir (p=0.01) 7

Resistance Concerns

Treatment-emergent resistance is a significant concern, particularly in younger patients and with delayed treatment. 1, 6, 9

• Resistance rates in clinical trials: 9.7% in phase 3 trial developed polymerase acidic protein variants (I38T/M/F substitutions) conferring reduced susceptibility 6
• Higher in children <5 years: This is the primary reason for the age restriction 1
• Delayed treatment increases resistance risk: Early administration is critical 9
• Human-to-human transmission of resistant strains: Documented but rare 10
• Resistance in severely immunocompromised: 7.2% of index patients developed resistance during follow-up 8

Alternative Treatments

Oseltamivir remains the first-line alternative and most widely used neuraminidase inhibitor. 2

Oseltamivir (Tamiflu)

• Dosing: Weight-based, twice daily for 5 days (treatment) or once daily for 7 days (prophylaxis) 2
• Age approval: Approved for treatment/prophylaxis in patients ≥1 year; can be used off-label in infants <1 year with specific dosing 2
• Advantages: Extensive safety data, approved for younger children, can be used in pregnancy
• Disadvantages: 5-day regimen (adherence issues), more GI side effects 7

Zanamivir (Relenza)

• Dosing: 10 mg (two 5-mg inhalations) twice daily for 5 days (treatment) or once daily for 7 days (prophylaxis) 2
• Age approval: ≥7 years for treatment, ≥5 years for prophylaxis 2
• Administration: Dry powder inhaler (Diskhaler device) 2
• Contraindication: NOT recommended for patients with chronic respiratory diseases (asthma, COPD) due to bronchospasm risk 2

Peramivir (Rapivab)

• Dosing: Single IV dose: 12 mg/kg (max 600 mg) for ages 6 months-12 years; 600 mg for ≥13 years 2
• Indication: Treatment only (not prophylaxis) 2
• Advantages: Single IV dose, useful when oral/inhaled routes not feasible
• Disadvantages: Requires IV access, dose adjustment needed for renal insufficiency 2

Clinical Decision Algorithm

Choose baloxavir when:

• Patient ≥5 years, otherwise healthy or high-risk (but not severely immunocompromised)
• Can present within 48 hours of symptom onset
• Single-dose adherence advantage is important
• Not pregnant or breastfeeding
• Can avoid polyvalent cations for several hours around dosing

Choose oseltamivir when:

• Patient <5 years of age
• Pregnant or breastfeeding
• Severely immunocompromised (resistance concerns with baloxavir)
• Concerns about resistance patterns in community
• Patient cannot avoid dairy/supplements

Choose zanamivir when:

• Oral route not feasible
• No chronic respiratory disease
• Patient ≥5 years

Choose peramivir when:

• Oral and inhaled routes not feasible
• Single-dose IV treatment needed
• Patient ≥6 months

Critical Pitfalls to Avoid

• Do not give baloxavir with dairy or supplements: This is the most common prescribing error that leads to treatment failure 2, 4
• Do not use in children <5 years: High resistance rates make this inappropriate 1
• Do not delay treatment: Efficacy decreases significantly after 48 hours, and delayed treatment increases resistance risk 9
• Do not use as monotherapy in severely immunocompromised: Resistance develops more readily 2
• Do not forget about bacterial superinfection: Baloxavir treats influenza but does not prevent secondary bacterial complications 1